Four years ago, Akebia Therapeutics was a company the FDA had just rejected, laying off nearly half its staff and watching its lead partner walk away. Today, that same drug, renamed Vafseo, is approved, on the market, and adding patients at a rate that would have looked like fantasy in 2022. The stock, meanwhile, trades below a dollar, and Nasdaq sent a formal warning letter in October. Two readings of the same company, and they cannot both be right for long.
The heart of it
The filed numbers show a business in genuine transition: one product growing, one collapsing, and the math of which wins out arriving in full force on January 1, 2027. The market is pricing the stock as if the outcome is already decided against them. The open question is whether Vafseo’s patient growth can fill the hole that Auryxia’s generics are digging; the Q4 2026 filing and the January 2027 TDAPA transition will be the next material data points on that question.
One product up, one in freefall
The 10-Q filed November 5, 2026, covering the quarter ended September 30, shows total revenue of $36.9 million, down 37% from the same quarter a year earlier. That headline number is doing two very different jobs at once.
Auryxia, a phosphate binder for dialysis patients that Akebia has sold for years, brought in $20 million in Q3 2026, compared with $42.5 million in Q3 2025. A generic entered the market in March 2026, and the math of generic competition is brutal and fast: branded revenue roughly halves, then keeps falling. Auryxia was once the company’s anchor. It is now an anchor of a different kind.
Vafseo, the anemia pill that the FDA rejected in 2022 and approved in March 2024, brought in $14.8 million in Q3, a modest dollar gain year over year. The patient count underneath it does not look modest at all: roughly 11,500 active patients at quarter’s end, a 140% increase from a year earlier. That gap between patient growth and revenue growth reflects inventory reductions at customers, a timing effect rather than a demand signal. The patient base is the durable number here.
The core tension in the filing is straightforward: Auryxia’s decline is mechanical and will continue; Vafseo’s growth is real but not yet large enough to cover the gap.
The cliff that arrives January 1
Vafseo currently earns a premium reimbursement rate from Medicare through a program called TDAPA, the Transitional Drug Add-on Payment Adjustment, which gives newly approved drugs a temporary bonus payment outside the standard dialysis bundle. That period expires December 31, 2026. Starting January 1, 2027, Vafseo gets paid through the standard bundle, and management projects per-patient annual revenue of roughly $1,000 to $1,500 post-transition, a meaningful step down from today’s rate.
This is the structural moment the whole filing points toward. The company has been building patient volume precisely because volume is the only lever available once the price per patient drops. Whether the math works depends on how many of those patients stay on therapy and how many more are added through 2027. The VOCAL trial results announced in November 2026, showing Vafseo met its primary endpoint of non-inferiority in maintaining hemoglobin versus an older injectable therapy, give the commercial team a clinical argument to make to dialysis centers. That matters for patient retention.
A new patent granted in November 2026, extending Vafseo’s protection into the early 2040s, removes one long-term risk. It does not change what happens in January.
Cash, debt, and the Nasdaq letter
The company held $159.3 million in cash at September 30, and operating activities used about $15 million over the first nine months of 2026. At that pace, cash alone covers many years of runway. On November 12, Akebia closed a new term loan with Symbiotic Capital, using the proceeds to retire an older loan from BlackRock. The new facility carries a rate of at least 11.5%, interest-only for five years, with principal due at maturity. Management says existing cash and revenues fund operations for at least two years.
The Nasdaq deficiency letter, received on October 21, gives the company until mid-April 2027 to get the stock back above a dollar for ten consecutive business days, or face delisting proceedings. At $0.41 as of our data, that requires the stock to more than double. Akebia has options, including a reverse stock split, but none of them change the underlying business. The letter is a compliance problem, not a solvency one, though the distinction matters less if the two arrive together.
The filed data shows a price-to-sales ratio of approximately 0.5. For context, the company’s decade median P/S has been approximately 1.8. IF revenue were to stabilize and IF the multiple were to revert toward that historical median, the arithmetic would point to a materially higher price, but both conditions carry significant uncertainty given the TDAPA transition and Auryxia’s ongoing decline.
The pipeline underneath
Akebia dosed the first patient in a Phase 2 trial for ebribafusp alfa, targeting rare complement-mediated kidney diseases including IgA nephropathy, in September 2026. Initial data is expected in 2027. A second mid-stage asset, praliciguat, is in development for a rare kidney condition called focal segmental glomerulosclerosis. Neither asset is close to generating revenue. Both represent the company’s argument that Vafseo is not the only thing it owns.
The pipeline represents a long-dated option on science with an uncertain payoff horizon. The commercial transition, by contrast, has a defined near-term catalyst in the January 2027 TDAPA change.
Reading the numbers
- Q3 2026 total revenue: $36.9 million. What it is: all product sales in the quarter ended September 30, 2026. What it means: the top line is shrinking fast because Auryxia is losing to generics faster than Vafseo is growing. Everyday terms: think of a shop where the old bestseller now has a cheaper knockoff next to it on the shelf, and the new product hasn’t yet matched what the old one used to sell.
- Auryxia Q3 revenue: $20 million, down from $42.5 million a year ago. What it is: net product revenue for the phosphate binder, filed in the Q3 2026 10-Q. What it means: generic entry in March 2026 cut revenue roughly in half in two quarters. Everyday terms: a family paying $425 a month for a branded medication now pays $200 for the generic version; the original maker’s income follows.
- Vafseo active patients: ~11,500, up 140% from Q3 2025. What it is: the count of patients actively taking the drug at quarter end. What it means: clinical adoption is accelerating even as revenue per patient is about to fall sharply. Everyday terms: a restaurant that doubled its table count but is about to cut its menu prices needs a lot more diners to keep the lights on.
- Cash: $159.3 million; nine-month operating cash use: $15 million. What it is: liquidity position and burn rate from the September 30 filing. What it means: at the current burn rate, cash alone covers many years, but the TDAPA transition could change the burn rate materially. Everyday terms: a household with $160,000 in savings spending $15,000 a year has time, but is about to take a pay cut.
- R&D spend: $16.2 million in Q3 2026. What it is: money spent on clinical trials and drug development in the quarter. What it means: nearly half of quarterly revenue is going back into the pipeline, which is either investment or distraction depending on how the commercial story resolves. Everyday terms: a small business spending nearly half its monthly sales on developing new products while its main product faces a price war.
Sources
- 10-Q for quarter ended September 30, 2026 (SEC EDGAR)
- Akebia Q3 2026 earnings release (ir.akebia.com)
- Symbiotic Capital term loan announcement (GlobeNewswire)
- FDA approval of Vafseo, March 2024 (Endpoints News)
- FDA Complete Response Letter, March 2022 (ir.akebia.com)
- Q3 2026 results analysis including analyst ratings (Tickeron)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)









